Please use this identifier to cite or link to this item:
Title: Targeting FGF21 for the treatment of nonalcoholic steatohepatitis
Author: Zarei, Mohammad
Pizarro Delgado, Javier
Barroso Fernández, Emma
Palomer Tarridas, Francesc Xavier
Vázquez Carrera, Manuel
Keywords: Inflamació
Malalties del fetge
Liver diseases
Issue Date: 26-Jan-2020
Publisher: Elsevier Current Trends
Abstract: Nonalcoholic steatohepatitis (NASH), the severe stage of nonalcoholic fatty liver disease (NAFLD), is defined as the presence of hepatic steatosis with inflammation, hepatocyte injury, and different degrees of fibrosis. Although NASH affects 2-5% of the global population, no drug has been specifically approved to treat the disease. Fibroblast growth factor 21 (FGF21) and its analogs have emerged as a potential new therapeutic strategy for the treatment of NASH. In fact, FGF21 deficiency favors the development of steatosis, inflammation, hepatocyte damage, and fibrosis in the liver, whereas administration of FGF21 analogs ameliorates NASH by attenuating these processes. We review mechanistic insights into the beneficial and potential side effects of therapeutic approaches targeting FGF21 for the treatment of NASH.
Note: Versió postprint del document publicat a:
It is part of: Trends in Pharmacological Sciences, 2020, vol. 41, num. 3, p. 199-208
Related resource:
ISSN: 0165-6147
Appears in Collections:Articles publicats en revistes (Institut de Biomedicina (IBUB))
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)

Files in This Item:
File Description SizeFormat 
699717.pdf722.79 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons